Anthem Biosciences Share Price: Jefferies Bull Case, Growth Outlook And Risks
Key Takeaways
- Anthem Biosciences Share Price sits at Rs 874.15 as of Friday, with a Rs 1,050 target implying about 20% upside.
- Jefferies values the stock at 65x September 2028 forward EPS, a 10% premium to the sector's ~60x forward multiple.
- Revenue is projected to grow 18% CAGR from FY26 to FY29, reaching Rs 34.86 billion by FY29, led by CRDMO.
- Risks include customer concentration and capacity expansion, with top two projects contributing over 30% of FY26 sales.
Anthem Biosciences Share Price stood at Rs 874.15 on Friday, signaling the latest price point as investors weigh a Jefferies bull case. The brokerage has assigned a valuation of 65 times its September 2028 estimated EPS, a 10% premium to the sector's one-year forward average of around 60 times. Jefferies argues Anthem's integrated CRDMO model lets customers move projects across discovery, development and manufacturing on a single platform, reducing friction and accelerating timelines.
Jefferies highlights Anthem's early bets on emerging therapeutic platforms such as oligonucleotides, peptides and antibody-drug conjugates (ADCs) as strategic differentiators. The bull case combines best-in-class RoCE with robust growth prospects, supported by an expanding CRDMO footprint and improved gross margins from backward integration.
Anthem Biosciences Share Price: Jefferies Bull Case And Growth Outlook
Jefferies notes Anthem delivered a RoCE of 25% in FY26, the highest among major Indian CRDMO players covered by the broker. The RoCE is expected to stay above 20% despite significant capacity expansion and higher capital expenditure. The brokerage forecasts an 18% CAGR in overall revenue from FY26 to FY29, with revenue rising from Rs 21.24 billion in FY26 to Rs 34.86 billion by FY29.
Manufacturing remains a key growth driver, with both existing commercial programs and new commercial programs contributing to the expansion. The research suggests Anthem's various business units could deliver 15-40% growth between FY26 and FY29, while new commercial projects are expected to be important contributors to the growth trajectory. The EBITDA is projected to rise from Rs 8.34 billion in FY26 to Rs 14.60 billion in FY29, a 21% CAGR, and EBITDA margins are expected to improve from 39% to around 42%, supported by operating leverage, capacity utilization and a stronger gross margin profile.
The gross margins are expected to expand by 50-80 basis points annually, aided by backward integration of Anthem's largest CRDMO product in FY26 with the full benefit realized in FY27. Net profit is projected to grow from Rs 5.92 billion in FY26 to Rs 10.16 billion in FY29, while EPS rises from Rs 10.4 to Rs 17.9. EPS growth is estimated at 18% in FY27, 15% in FY28 and 26% in FY29.
As with any stock, the upside hinges on execution and risk management. The near-term triggers Jefferies sees include the launch of new commercial molecules, the scale-up of CDMO molecules launched in FY26, and the commercialization of a biosimilar for a large pharmaceutical customer. On the flip side, customer concentration remains a risk: Anthem's top two projects accounted for more than 30% of FY26 sales, and its partnership with Davos accounts for around 15% of FY26 sales in the US market. Capacity expansion is another dynamic to watch; Jefferies expects Anthem to be among the leading CRDMO spenders in FY27, while the company is expected to remain net cash in the coming years.
Understanding The Anthem Biosciences CDMO Advantage And Early Stage Investments
At the core is Anthem's CRDMO model–a contract research, development and manufacturing organization that supports customers across the drug development lifecycle. This integrated approach reduces project handoffs and speeds time to market, a critical edge as customers seek to de-risk pipelines and accelerate clinical programs. Anthem's strategic investments in oligonucleotides, peptides and ADCs position the company to capture opportunities in high-growth modalities, reinforcing its position in the healthcare outsourcing space.
This business model translates into a geography-agnostic client base, with a US market emphasis and strategic partnerships such as the one with Davos. For stock readers, the dominant question is how this platform translates to earnings durability: the scaling of CDMO programs, the successful deployment of new molecules, and the ability to translate production capacity into incremental revenue without eroding margins.
Within this framework, the stock's momentum also ties back to the "Anthem Biosciences Stock" narrative. Investors looking at the overall outperformance of Indian CRDMO players should compare Anthem's value proposition against peers that emphasize either discovery services or manufacturing-only capabilities. The emphasis on backward integration and a stronger business mix suggests margin expansion could prove sticky, supporting a high RoCE profile even with continued capex.
As part of Swastika's ecosystem, investors can leverage Swastika's Sarthi AI stock assistant, for deeper stock analysis and scenario planning. This AI assistant helps translate complex earnings trajectories into actionable insights and can be a practical tool to stress-test models around regulatory changes, clinical trial outcomes and capacity expansions that affect Anthem's long-term trajectory.
Revenue Growth, Margin Expansion, And FY29 Outlook
The revenue story remains central to the bull case. Anthem's overall revenue is projected to grow at an 18% CAGR between FY26 and FY29, driven primarily by its CRDMO business. Revenue is expected to increase from Rs 21.24 billion in FY26 to Rs 34.86 billion by FY29, a climb that implies both ramp-up in existing programs and the successful introduction of new commercial molecules. This expansion dovetails with a higher EBITDA and improving margins: EBITDA is forecast to rise from Rs 8.34 billion in FY26 to Rs 14.60 billion in FY29, an 21% CAGR, with EBITDA margins moving from 39% to about 42% by FY29.
Gross margins are expected to improve by 50-80 basis points annually, supported by backward integration of Anthem's largest CRDMO product in FY26 and the improved mix from the CDMO platform. The synergy of higher capacity utilization, better operating leverage and a stronger gross margin profile underpins the expansion in ROCE, which Jefferies projects staying above 20% even as capex intensifies. The net profit story mirrors this trajectory: Rs 5.92 billion in FY26 to Rs 10.16 billion in FY29, with EPS rising from Rs 10.4 to Rs 17.9. The path is not linear; EPS growth is forecast at 18% in FY27, 15% in FY28 and 26% in FY29, underscoring the power of scale, improved margins and a diversified product mix.
Near-Term Triggers, Risks, And Capex Dynamics
Three key near-term triggers matter for Anthem's stock: the launch of new commercial molecules, the scale-up of CDMO molecules launched in FY26, and the commercialization of a biosimilar for a large pharmaceutical customer. Each trigger could substantiate the earnings trajectory laid out by Jefferies and push the Anthem Biosciences share price higher as the business executes. Investors should watch how the company manages customer concentration risk as well as its capital expenditure plans to expand capacity–Jefferies expects Anthem to be among the leading CRDMO spenders in FY27, which could press margins if not matched by demand. The company is expected to stay net cash in the coming years, a factor that could ease funding for capex while preserving optionality for future M&A or partnering opportunities.
Beyond the near-term, a crucial factor is capacity expansion. If Anthem can sustain growth in both existing programs and new commercial projects while maintaining–or further improving–gross and EBITDA margins, the risk-reward becomes favorable for longer-horizon investors. There is an additional dynamic: the presence of a Davos partnership that accounted for around 15% of FY26 sales underscores the US-market exposure and strategic alignment that can translate into recurring revenue streams. The trajectory remains dependent on the pace of new molecule launches and biosimilar milestones, which could become the next major catalysts for the stock.
Current Price Momentum And What It Signals For Investors
Looking at the latest price action, Anthem Biosciences share price is currently Rs 874.15, with Friday's move showing a slight decline of 0.04%. The stock has gained 10.44% over the past month and 36.99% so far in 2026, while it is up 3.28% over the past year. The implied upside from Jefferies' Rs 1,050 target is about 20.1%, indicating the market may not have fully priced the CRDMO-growth thesis yet. The combination of a premium valuation (65x September 2028 forward EPS, a 10% premium to the sector's forward average of around 60x) and a multi-year growth path creates a rare mix for a mid-cap Indian CRO-like business.
| Time Frame | Return |
|---|---|
| Past Month | 10.44% |
| 2026 YTD | 36.99% |
| Past Year | 3.28% |
Investors should weigh this momentum with caution. The stock trades at a premium versus sector peers, and the key to upside is disciplined capex management, successful execution of new programs, and a broadening revenue mix that shields margins from production cost pressures. Given Anthem's net cash position implied by Jefferies and the ongoing capex cycle, the risk-reward remains compelling for those who can tolerate a premium multiple in exchange for stronger growth and a higher ROCE.
Frequently Asked Questions
What is Anthem Biosciences share price currently?
As of Friday, Anthem Biosciences share price is Rs 874.15.
What is Anthem Biosciences target price?
Jefferies has a Rs 1,050 target price on Anthem Biosciences, implying roughly 20% upside.
What is Anthem Biosciences CDMO?
Anthem is an integrated contract research, development and manufacturing organization (CRDMO) enabling customers to move projects across discovery, development and manufacturing on a single platform.
What is the revenue outlook for Anthem Biosciences through FY29?
Jefferies expects revenue to grow 18% CAGR from FY26 to FY29, from Rs 21.24 billion in FY26 to Rs 34.86 billion by FY29.
What are the key risks and triggers for Anthem Biosciences stock?
Near-term triggers include the launch of new commercial molecules, the scale-up of CDMO molecules launched in FY26, and biosimilar commercialization for a large pharmaceutical customer. Key risks include customer concentration (top two projects >30% of FY26 sales) and a Davos partnership accounting for around 15% of FY26 sales in the US market; capex plans and net cash position will influence upside.
Conclusion
Anthem Biosciences shares stand at a crossroads where a durable CRDMO-driven growth path could sustain premium valuations and deliver durable upside for the patient investor. The Rs 874.15 price and the Rs 1,050 target imply roughly 20% upside, supported by a 65x forward earnings multiple and a sector premium. The key to unlocking the full potential lies in successful execution of new drugs, scale-up of CDMO programs and continued margin expansion from backward integration–while managing customer concentration and capex risk.
Open your trading and demat account here
Reference :
1 : Economictimes
